CN1161340C - 为玻连蛋白受体拮抗剂的苯并咪唑化合物 - Google Patents

为玻连蛋白受体拮抗剂的苯并咪唑化合物 Download PDF

Info

Publication number
CN1161340C
CN1161340C CN99815842.9A CN99815842A CN1161340C CN 1161340 C CN1161340 C CN 1161340C CN 99815842 A CN99815842 A CN 99815842A CN 1161340 C CN1161340 C CN 1161340C
Authority
CN
China
Prior art keywords
compound
resin
alkyl
aryl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN99815842.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN1333755A (zh
Inventor
B��R��ŵ��˹����
B·R·诺伊斯塔特
ʷ
E·M·史密斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of CN1333755A publication Critical patent/CN1333755A/zh
Application granted granted Critical
Publication of CN1161340C publication Critical patent/CN1161340C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN99815842.9A 1998-11-30 1999-09-29 为玻连蛋白受体拮抗剂的苯并咪唑化合物 Expired - Fee Related CN1161340C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20161198A 1998-11-30 1998-11-30
US09/201611 1998-11-30

Publications (2)

Publication Number Publication Date
CN1333755A CN1333755A (zh) 2002-01-30
CN1161340C true CN1161340C (zh) 2004-08-11

Family

ID=22746536

Family Applications (1)

Application Number Title Priority Date Filing Date
CN99815842.9A Expired - Fee Related CN1161340C (zh) 1998-11-30 1999-09-29 为玻连蛋白受体拮抗剂的苯并咪唑化合物

Country Status (12)

Country Link
EP (1) EP1135374B9 (enExample)
JP (1) JP4480117B2 (enExample)
CN (1) CN1161340C (enExample)
AR (1) AR021427A1 (enExample)
AT (1) ATE338751T1 (enExample)
AU (1) AU1908400A (enExample)
CA (1) CA2353063C (enExample)
CO (1) CO5140112A1 (enExample)
DE (1) DE69933135T2 (enExample)
ES (1) ES2273517T3 (enExample)
PE (1) PE20001427A1 (enExample)
WO (1) WO2000032578A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010112408A (ko) * 1999-04-07 2001-12-20 모리타 다카카즈 Ｎ-치환되고-Ｎ'-치환된 우레아 유도체 및 ＴＮＦ-α 생성억제제로서의 그의 용도
PL352367A1 (en) * 1999-05-17 2003-08-25 Novo Nordisk As Glucagon antagonists/inverse agonists
FR2809396B1 (fr) 2000-05-24 2005-10-14 Centre Nat Rech Scient Nouvelles molecules possedant une activite calcimimetique et leur mode de preparation
US6562807B2 (en) 2000-06-23 2003-05-13 Novo Nordisk A/S Glucagon antagonists/inverse agonists
WO2008148845A2 (en) 2007-06-07 2008-12-11 Novozymes A/S Method of preparing a dough-based product
EP2595488B1 (en) 2010-07-21 2019-12-04 Novozymes A/S Process for preparing a baked product with anti-staling amylase and peptidase
WO2015121210A1 (en) 2014-02-11 2015-08-20 Bayer Pharma Aktiengesellschaft Benzimidazol-2-amines as midh1 inhibitors
US9951027B2 (en) 2014-02-11 2018-04-24 Bayer Pharma Aktiengesellschaft Benzimidazol-2-amines as MIDH1 inhibitors
CN104694290A (zh) * 2014-05-07 2015-06-10 宁波职业技术学院 一种洗脚皂
US10138226B2 (en) 2014-10-23 2018-11-27 Bayer Pharma Aktiengesellschaft Benzimidazol-2-amines as MIDH1 inhibitors
CN107108554B (zh) 2014-10-23 2020-11-06 德国癌症研究中心 作为midh1抑制剂用于治疗肿瘤的1-环己基-2-苯基氨基苯并咪唑
CA2988356A1 (en) 2015-06-08 2016-12-15 Bayer Pharma Aktiengesellschaft N-menthylbenzimidazoles as midh1 inhibitors
CA2992364A1 (en) 2015-07-16 2017-01-19 Bayer Pharma Aktiengesellschaft 5-hydroxyalkylbenzimidazoles as midh1 inhibitors
TW202146416A (zh) 2019-12-11 2021-12-16 德商拜耳廠股份有限公司 吡唑并三𠯤
AU2021231312A1 (en) 2020-03-06 2022-08-25 Bayer Aktiengesellschaft Imidazotriazines acting on cancer via inhibition of CDK12

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10501222A (ja) * 1994-05-27 1998-02-03 メルク エンド カンパニー インコーポレーテッド 破骨細胞仲介骨吸収を抑制するための化合物
BR9508178A (pt) * 1994-06-29 1997-11-18 Smithkline Beecham Corp Antagonistas de receptor de vitronectina

Also Published As

Publication number Publication date
WO2000032578A8 (en) 2002-02-07
ATE338751T1 (de) 2006-09-15
WO2000032578A1 (en) 2000-06-08
PE20001427A1 (es) 2000-12-18
CA2353063C (en) 2009-06-16
ES2273517T3 (es) 2007-05-01
CA2353063A1 (en) 2000-06-08
CN1333755A (zh) 2002-01-30
AU1908400A (en) 2000-06-19
DE69933135D1 (de) 2006-10-19
DE69933135T2 (de) 2007-08-09
AR021427A1 (es) 2002-07-17
JP2002531441A (ja) 2002-09-24
EP1135374A1 (en) 2001-09-26
JP4480117B2 (ja) 2010-06-16
EP1135374B1 (en) 2006-09-06
EP1135374B9 (en) 2007-02-21
CO5140112A1 (es) 2002-03-22

Similar Documents

Publication Publication Date Title
CN1161340C (zh) 为玻连蛋白受体拮抗剂的苯并咪唑化合物
CN1143855C (zh) 作为抗凝剂的邻氨基苯甲酰胺衍生物
CN1150171C (zh) 二环杂环,含这些化合物的药物组合物,及其制备方法
CN1110305C (zh) 作为抗凝剂的萘基取代的苯并咪唑衍生物
CN1193018C (zh) 杂环衍生物及其医药用途
CN1192773C (zh) 环胺ccr3拮抗剂
CN1134423C (zh) 粘连受体拮抗剂
CN1659148A (zh) 芳基肟化合物
CN1218471A (zh) 咔啉衍生物
CN1214011C (zh) 作为整联蛋白拮抗剂的间－氮杂环氨基苯甲酸化合物及其衍生物
CN1353694A (zh) α－取代羧酸衍生物
CN1688550A (zh) 作为金属蛋白酶mmp12抑制剂的2,5－二氧代咪唑烷－4－基乙酰胺及类似物
CN1788001A (zh) 可用于治疗赘生性疾病、炎性和免疫系统病症的2,4－二(苯氨基)嘧啶
CN1431999A (zh) 具有血管损伤活性的吲哚衍生物
CN1060841A (zh) 喹唑啉衍生物及其制备方法
CN1157288A (zh) 苯并咪唑衍生物，其制备方法和其医疗用途
CN1578665A (zh) 4型磷酸二脂酶抑制剂及其应用
CN1274669C (zh) 适合用于治疗阿尔茨海默病或老年性痴呆的氟代苯甲酰胺
CN101031555A (zh) 具有vap－1抑制活性的噻唑衍生物
CN1170842C (zh) 新的脒基苄基胺衍生物及其作为凝血酶抑制剂的用途
CN1035817C (zh) 三唑基取代的叔胺化合物及其盐的制备方法
CN1516695A (zh) 用作抗病毒剂的芳基磺酰胺类化合物
CN1745065A (zh) 4－氧代－3－(1－氧代－1h－异喹啉－2－基乙酰氨基)－戊酸酯和酰胺衍生物及其作为天冬氨酸特异性半胱氨酸蛋白酶抑制剂的用途
CN1291979C (zh) 咪唑化合物及其作为腺苷脱氨酶抑制剂的用途
CN1921859A (zh) 用于治疗骨疾病的吲哚衍生物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CI01 Publication of corrected invention patent application

Correction item: International application date

Correct: 19991129

False: 19990929

Number: 32

Page: 441

Volume: 20

CI03 Correction of invention patent

Correction item: International application date

Correct: 19991129

False: 19990929

Number: 32

Page: The title page

Volume: 20

COR Change of bibliographic data

Free format text: CORRECT: INTERNATIONAL APPLICATION DATE; FROM: 1999.9.29 TO: 1999.11.29

ERR Gazette correction

Free format text: CORRECT: INTERNATIONAL APPLICATION DATE; FROM: 1999.9.29 TO: 1999.11.29

CI01 Publication of corrected invention patent application

Correction item: Application Date

Correct: Application Date:1999.11.29 International filing date:1999.11.29

False: Application Date:1999.09.29 International filing date:1999.09.29

Number: 32

Page: 441

Volume: 20

CI03 Correction of invention patent

Correction item: Application Date

Correct: Application Date:1999.11.29 International filing date:1999.11.29

False: Application Date:1999.09.29 International filing date:1999.09.29

Number: 32

Page: The title page

Volume: 20

COR Change of bibliographic data

Free format text: CORRECT: APPLICATION DATE; FROM: APPLICATION DATE:1999.9.29 INTERNATIONAL APPLICATION DATE:1999.9.29 TO: APPLICATION DATE:1999.11.29 INTERNATIONAL APPLICATION DATE:1999.11.29

ERR Gazette correction

Free format text: CORRECT: APPLICATION DATE; FROM: APPLICATION DATE:1999.9.29 INTERNATIONAL APPLICATION DATE:1999.9.29 TO: APPLICATION DATE:1999.11.29 INTERNATIONAL APPLICATION DATE:1999.11.29

C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee